Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.870
+0.020 (1.08%)
At close: May 12, 2025, 4:00 PM
1.831
-0.039 (-2.10%)
After-hours: May 12, 2025, 6:03 PM EDT
Immutep Revenue
Immutep had revenue of 3.15M AUD in the half year ending December 31, 2024, with 86.75% growth. This brings the company's revenue in the last twelve months to 4.88M, up 24.11% year-over-year. In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M with 9.59% growth.
Revenue (ttm)
4.88M AUD
Revenue Growth
+24.11%
P/S Ratio
89.42
Revenue / Employee
157,381 AUD
Employees
31
Market Cap
269.98M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
| Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
| Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
| Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
| Jun 30, 2020 | 13.74M | 8.10M | 143.72% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IMMP News
- 4 days ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 5 weeks ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire
- 3 months ago - Immutep Limited: Continuing To Make The Case For Eftilagimod - Seeking Alpha
- 5 months ago - Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewsWire
- 5 months ago - Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 - GlobeNewsWire
- 6 months ago - Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients - Seeking Alpha
- 6 months ago - Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial - Benzinga